Salute e Benessere

Sobi Q3 2024 report: Strong growth and significant pipeline momentum

Outlook 2024 - Updated Outlook 2024 - Updated Clickherefor the Financial Summary. * The strategic portfolio includes Sobi's medicines Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant®, Vonjo® and Zynlonta®, and royalty on Sanofi's sales of Altuviiio® and Beyfortus. Investors, analysts, and the media are invited to a conference call on the same day at 14:00 CEST,13:00 BST, and08:00 EDT. The call will include a presentation of the results and a Q&A session. The...
PR Newswire
24/10/2024

Pierre Fabre announce 1st Patient Dosed in Phase I/II of PFL-002/VERT-002, a…

CASTRES, France, Oct. 24, 2024 /PRNewswire/ -- Pierre Fabre Laboratories announced today that the first patient has been dosed with PFL-002/VERT-002, a monoclonal antibody acting as a degrader of c-MET, in a phase I/II first-in-human dose-escalation, dose-optimization and dose-expansion trial, for patients with Non-Small Cell Lung Cancer (NSCLC) harbouring MET alterations. CASTRES,France , Oct. 24, 2024 /PRNewswire/ -- Pierre Fabre Laboratories announced today that the first patient has...
PR Newswire
24/10/2024

Meiyume Debuts at Cosmopack Asia 2024: "Elevate: Reaching New Heights in Beauty…

Elevating Towards a Sustainable FutureSustainability is core to Meiyume's operations. At Cosmopack, visitors can explore eco-friendly packaging materials and achievements in green manufacturing processes. Meiyume's latest sustainable achievements will be highlighted, including a Cosmotalks panel on 12th November, titled "Look Beyond the Label: Consumer Expectations for Sustainable Beauty," where Meiyume will share insights on how sustainability, technology, and data are reshaping the…
PR Newswire
24/10/2024

Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD

CTAD Lifetime Achievement Award October 29, 4:20 p.m. to 4:55 p.m. (CET) CTAD Lifetime Achievement Award October 29,4:20 p.m. to 4:55 p.m. (CET) Late Breaking Symposium 1 – The AHEAD 3-45 Study: Design and Results of a Novel Screening Process for a Preclinical AD Trial From6:10 to 6:50 p.m. (CET)onOctober 29(Tuesday). This late breaking symposium will present the design of the AHEAD 3-45 trial focused on lecanemab in pre-clinical Alzheimer's disease and the findings on use...
PR Newswire
24/10/2024

Indivior Announces Q3 2024 Financial Results

Webcast link: https://edge.media-server.com/mmc/p/ppm4ske8Participants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BId4d5b45a6f3e4291ba42150c1620fc64(Registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration) Webcast link:https://edge.media-server.com/mmc/p/ppm4ske8Participants may access the presentation...
PR Newswire
24/10/2024

ONWARD® Medical Successfully Raises EUR 50 Million in an Upsized Capital…

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Ottobock, a global leader in the fields of prosthetics, orthotics and exoskeleton technology, acquires c.10% of ONWARD Medical N.V.'s share capital and initiates strategic relationshipCash runway extended to two years or moreCapital increase was upsized to EUR 50M on the basis of strong demand from high-quality long-only and sector specialist...
Nasdaq GlobeNewswire
24/10/2024

Essity: Interim Report, Quarter 3, 2024

CEO'S COMMENTS CEO'S COMMENTS The third quarter was characterized by strong earnings with profitable growth and record-high cash flow. Our focus on growth resulted in higher volumes and increased market shares all over the world. Volume growth and higher market shares Every day Essity cares for the hygiene and health of a billion people across 150 countries. Our solutions are needed regardless of the economic situation and we are working to constantly increase the value of...
PR Newswire
24/10/2024

J INTS BIO Presents Interim Findings from Phase 1/2 Clinical Trial of…

Mutations in the epidermal growth factor receptor (EGFR) is a key driver in the pathogenesis of NSCLC, with 3rd Generation EGFR-TKIs like osimertinib serving as the cornerstone of treatment. Unfortunately, eventually resistance to this treatment will occur, leading to cancer relapse and disease progression. JIN-A02, developed by J INTS BIO, is the 4th-generation EGFR-TKI specifically designed to address this. By targeting both the original mutations and those acquired subsequently as a result of…
PR Newswire
24/10/2024

Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer…

Ribociclib (Kisqali) plus aromatase inhibitor (AI) recommended for HR+/HER2- early breast cancer (EBC) node-positive and high-risk node-negative patients, as studied in the NATALEE trial and indicated by the FDA 1 Recommendation comes after recent FDA approval and positive CHMP Opinion for ribociclib (Kisqali) to help reduce the risk of recurrence in EBCRibociclib (Kisqali) is also the only Category 1 preferred CDK4/6 inhibitor for first-line treatment of patients with...
Nasdaq GlobeNewswire
24/10/2024

Pharming Group reports third quarter 2024 financial results and provides…

Third quarter 2024 total revenues increased by 12% to US$74.8 million, compared to the third quarter 2023, driven by continued strong RUCONEST® and Joenja® revenue growthRUCONEST® third quarter revenue increased by 6% to US$63.6 million, compared to the third quarter 2023Joenja® (leniolisib) third quarter revenue increased by 72% to US$11.2 million, compared to the third quarter 2023 First nine months total revenues increased by 25% to US$204.5 million, compared...
Nasdaq GlobeNewswire
24/10/2024

PolTREG launches Phase 2 cell therapy trial in children with presymptomatic…

Treating diabetes patients earlier with PTG-007 could provide functional cureRecruitment will go ahead after European Medicines Agency approvalCompany has 12 years' worth of safety and efficacy data for PTG-007 Gdańsk, Poland – 24 October 2024 (07:00 CET)– PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cellular therapies for a wide range of autoimmune diseases, has launched a placebo-controlled Phase 2 clinical...
Nasdaq GlobeNewswire
24/10/2024

J INTS BIO Presents Interim Results from the Preclinical Study of 'JIN-001' in…

Ovarian cancer remains one of the most aggressive and lethal gynecological malignancies, with approximately 70% of patients diagnosed at an advanced stage. While many patients initially respond to standard chemotherapy, drug resistance eventually develops, leading to disease progression and cancer relapse. JIN-001 was designed to address this issue and by targeting heat shock protein 90 (HSP90), a molecular chaperone that plays a crucial role in enabling cancer cells to adapt to therapeutic…
PR Newswire
24/10/2024

Casio to Release MR-G Inspired by the Brilliant Gleam of Japanese Katana Swords

The distinctive shock-resistant MRG-B2000JS design is based on the Juryoku-Maru: San motif, evoking its extraordinary shape and expressing the traditional techniques and aesthetics unique to Japanese katana swords. The recrystallized hybrid titanium bezel with its unique temper pattern is made in layers of Ti64 and pure titanium that are subjected to high-temperature, high-pressure compression. This material is then cut, polished, and recrystallized to replicate the beautiful blade pattern of…
PR Newswire
24/10/2024

Hope Medicine Inc. Announces Positive Results from a Global Phase 2 Study of a…

The mean non-menstrual pelvic pain score was reduced by 50% The mean non-menstrual pelvic pain score was reduced by 50% Most of the patients reported normal menstrual periods No typical peri-menopausal symptoms were reported There were no significant changes in bone mineral density or key sex hormone levels About 190 million women worldwide suffer from endometriosis, making up a market size of$200 billion SHANGHAI , Oct. 24, 2024 /PRNewswire/ -- Hope Medicine...
PR Newswire
24/10/2024

Anti-CD38 mAb Market to Accelerate Substantially During the Study Period…

Key Takeaways from the Anti-CD38 mAb Market Report Key Takeaways from the Anti-CD38 mAb Market Report Discover which therapies are expected to grab the anti-CD38 mAb market share @Anti-CD38 mAb Market Report Anti-CD38 mAb Market Dynamics The market for anti-CD38 mAbs has undergone significant growth and transformation in recent years, driven primarily by theincreasing prevalence of multiple myelomaand the d emand for more effective treatment options. The market...
PR Newswire
23/10/2024

/DISREGARD RELEASE: Osteotec/

PR Newswire
23/10/2024

Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November…

Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations...
PR Newswire
23/10/2024

Piramal Pharma Limited Announces Results for Q2 and H1 FY25

Key Highlights for Q2FY25 Nandini Piramal, Chairperson, Piramal Pharma Limitedsaid, "We continue our momentum of delivering healthy revenue growth accompanied by YoY EBITDA margin expansion. This has been primarily driven by consistent growth in our CDMO business which has witnessed a good pick-up in innovation related work and on-patent commercial revenues. To sustain this growth momentum and to capitalize on rising demand for sterile fill-finish capabilities, we have announced...
PR Newswire
23/10/2024

Saudi Surgeon Honored for Performing the World's First Fully Robotic Heart…

"Robotic Heart Surgery" at KFSHRC…A Leading and Accelerating Journey of Success RIYADH, Saudi Arabia, Oct.23, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) continues to set itself apart by providing innovative specialized healthcare services, particularly through its robotic heart surgery program which has experienced accelerated success since its establishment in 2019. In its first year, the program performed 105 robotic heart surgeries…
Nasdaq GlobeNewswire
23/10/2024

Residential Bathroom Pods Market Size to Grow USD 1816.8 Million by 2030 at a…

The Global Residential Bathroom Pods Market was valued at USD 1081 Million in 2023 and is anticipated to reach USD 1816.8 Million by 2030, witnessing a CAGR of 8.3% during the forecast period 2024-2030. The Global Residential Bathroom Pods Market was valued atUSD 1081 Millionin 2023 and is anticipated to reachUSD 1816.8 Millionby 2030, witnessing a CAGR of 8.3% during the forecast period 2024-2030. Get Free Sample: ...
PR Newswire
23/10/2024

Sterilization Equipment Market to be Worth $26.77 Billion by 2031--Exclusive…

Sterilization equipment is a crucial component in the healthcare industry for preventing the spread of infectious diseases. These diseases are caused by pathogenic microorganisms, including bacteria, viruses, parasites, and fungi. They can be transmitted directly or indirectly—from person to person, through the use of infected or non-sterilized medical devices, or within contaminated healthcare environments. To mitigate the incidence of infectious diseases, healthcare facilities are increasingly…
PR Newswire
23/10/2024

KFSHRC Performs World First Robotic Left Liver Lobe Transplant

Novel Technique Hopes to Extend Robotic Transplant to More Patients RIYADH, Saudi Arabia, Oct.23, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) has achieved another world first by performing a fully robotic left lobe liver transplant from a living donor. The novel technique led by Prof. Dieter Broering, the Executive Director of the Organ Transplant Center of Excellence, promises all the benefits of robotic transplant - increased precision,...
Nasdaq GlobeNewswire
23/10/2024

Bi-Metal Band Saw Blade Market Size to Grow USD 1939.3 Million by 2939 at a CAR…

Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-35Q11964/Global_Bi_Metal_Band_Saw_Blade_Market Get Free Sample:https://reports.valuates.com/request/sample/QYRE-Auto-35Q11964/Global_Bi_Metal_Band_Saw_Blade_Market Major Factors Driving the Growth of Bi-Metal Sand Saw Blade Market: The Bi-Metal Band Saw Blade Market is set to continue growing as industries worldwide demand more efficient and durable cutting tools. The rise in industrial manufacturing, metal...
PR Newswire
23/10/2024

Major shareholder announcement

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments.Per October 22, 2024, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,548,644 shares, corresponding to 5.02% (previously 4.92%) of the total share capital attached to shares. The combined total of share...
Nasdaq GlobeNewswire
23/10/2024
Altri  Comunicati